GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » Market Cap

Blueprint Medicines (LTS:0HOJ) Market Cap : $5,725.3 Mil (As of Mar. 15, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Blueprint Medicines Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Blueprint Medicines's share price for the quarter that ended in Dec. 2024 was $86.75. Blueprint Medicines's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 63.7 Mil. Therefore, Blueprint Medicines's market cap for the quarter that ended in Dec. 2024 was $5,527.0 Mil.

Blueprint Medicines's quarterly market cap declined from Jun. 2024 ($6,698.4 Mil) to Sep. 2024 ($5,782.7 Mil) and declined from Sep. 2024 ($5,782.7 Mil) to Dec. 2024 ($5,527.0 Mil).

Blueprint Medicines's annual market cap increased from Dec. 2022 ($2,598.0 Mil) to Dec. 2023 ($5,613.3 Mil) but then declined from Dec. 2023 ($5,613.3 Mil) to Dec. 2024 ($5,527.0 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Blueprint Medicines's Enterprise Value for Today is $5,579.0 Mil.


Blueprint Medicines Market Cap Historical Data

The historical data trend for Blueprint Medicines's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Market Cap Chart

Blueprint Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,157.79 6,010.91 2,598.02 5,613.29 5,527.02

Blueprint Medicines Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,613.29 5,915.76 6,698.44 5,782.65 5,527.02

Competitive Comparison of Blueprint Medicines's Market Cap

For the Biotechnology subindustry, Blueprint Medicines's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Market Cap distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Market Cap falls into.



Blueprint Medicines Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Blueprint Medicines's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as

Market Cap (A: Dec. 2024 )=Share Price (A: Dec. 2024 )*Shares Outstanding (EOP) (A: Dec. 2024 )
=$86.75*63.712
=$5,527.0

Blueprint Medicines's Market Cap for the quarter that ended in Dec. 2024 is calculated as

Market Cap (Q: Dec. 2024 )=Share Price (Q: Dec. 2024 )*Shares Outstanding (EOP) (Q: Dec. 2024 )
=$86.75*63.712
=$5,527.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Blueprint Medicines  (LTS:0HOJ) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Blueprint Medicines Market Cap Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Blueprint Medicines Headlines

No Headlines